Angiogenesis Genotyping and Clinical Outcomes in Patients with Advanced Hepatocellular Carcinoma Receiving Sorafenib: The ALICE-2 Study
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Angiogenesis Genotyping and Clinical Outcomes in Patients with Advanced Hepatocellular Carcinoma Receiving Sorafenib: The ALICE-2 Study
Authors
Keywords
-
Journal
Targeted Oncology
Volume 15, Issue 1, Pages 115-126
Publisher
Springer Science and Business Media LLC
Online
2020-02-04
DOI
10.1007/s11523-020-00698-x
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Results of KEYNOTE-240: phase 3 study of pembrolizumab (Pembro) vs best supportive care (BSC) for second line therapy in advanced hepatocellular carcinoma (HCC).
- (2019) Richard S. Finn et al. JOURNAL OF CLINICAL ONCOLOGY
- Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial
- (2018) Masatoshi Kudo et al. LANCET
- Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
- (2018) Andrew X Zhu et al. LANCET ONCOLOGY
- Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma
- (2018) Ghassan K. Abou-Alfa et al. NEW ENGLAND JOURNAL OF MEDICINE
- REACH-2: A randomized, double-blind, placebo-controlled phase 3 study of ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma (HCC) and elevated baseline alpha-fetoprotein (AFP) following first-line sorafenib.
- (2018) Andrew X. Zhu et al. JOURNAL OF CLINICAL ONCOLOGY
- Multicenter Prospective Study of Angiogenesis Polymorphism Validation in HCC Patients Treated with Sorafenib. An INNOVATE Study Protocol
- (2018) Andrea Casadei Gardini et al. TUMORI
- Ten years of sorafenib in hepatocellular carcinoma: Are there any predictive and/or prognostic markers?
- (2018) Giorgia Marisi et al. WORLD JOURNAL OF GASTROENTEROLOGY
- Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma
- (2017) Austin G. Duffy et al. JOURNAL OF HEPATOLOGY
- Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2017) Jordi Bruix et al. LANCET
- Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial
- (2017) Anthony B El-Khoueiry et al. LANCET
- Metronomic capecitabine versus best supportive care as second-line treatment in hepatocellular carcinoma: a retrospective study
- (2017) Andrea Casadei Gardini et al. Scientific Reports
- Mechanism and consequences of RAF kinase activation by small-molecule inhibitors
- (2014) M Holderfield et al. BRITISH JOURNAL OF CANCER
- New biological perspectives for the improvement of the efficacy of sorafenib in hepatocellular carcinoma
- (2014) Antoine Galmiche et al. CANCER LETTERS
- Autocrine vascular endothelial growth factor signaling promotes cell proliferation and modulates sorafenib treatment efficacy in hepatocellular carcinoma
- (2014) Sui Peng et al. HEPATOLOGY
- VEGF and VEGFR genotyping in the prediction of clinical outcome for HCC patients receiving sorafenib: The ALICE-1 study
- (2014) Mario Scartozzi et al. INTERNATIONAL JOURNAL OF CANCER
- A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C
- (2013) Bruno Sangro et al. JOURNAL OF HEPATOLOGY
- Expression and Correlation of Hypoxia-inducible Factor-1α, Vascular Endothelial Growth Factor and Microvessel Density in Experimental Rat Hepatocarcinogenesis
- (2013) W Wang et al. JOURNAL OF INTERNATIONAL MEDICAL RESEARCH
- The relation of vascular endothelial growth factor (VEGF) gene polymorphisms on VEGF levels and the risk of vasoocclusive crisis in sickle cell disease
- (2012) Hebah H. Al-Habboubi et al. EUROPEAN JOURNAL OF HAEMATOLOGY
- Genetics of VEGF Serum Variation in Human Isolated Populations of Cilento: Importance of VEGF Polymorphisms
- (2011) Daniela Ruggiero et al. PLoS One
- Evolving strategies for the treatment of hepatocellular carcinoma: From clinical-guided to molecularly-taylored therapeutic options
- (2010) Luca Faloppi et al. CANCER TREATMENT REVIEWS
- VEGF −460T → C polymorphism and its association with VEGF expression and outcome to FOLFOX-4 treatment in patients with colorectal carcinoma
- (2010) M-H Chen et al. PHARMACOGENOMICS JOURNAL
- Influence of theVEGF-A936C>T germinal polymorphism on tumoral VEGF expression in head and neck cancer
- (2009) Jean-Louis Formento et al. PHARMACOGENOMICS
- Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial
- (2008) Ann-Lii Cheng et al. LANCET ONCOLOGY
- Sorafenib in Advanced Hepatocellular Carcinoma
- (2008) Josep M. Llovet et al. NEW ENGLAND JOURNAL OF MEDICINE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now